Trading Report: Today: Relmada Therapeutics Inc (RLMDD) Upgrade at The Zacks Investment Research

Today: Relmada Therapeutics Inc (RLMDD) Upgrade at The Zacks Investment Research

Zacks Investment Research upgraded shares of Relmada Therapeutics Inc (NASDAQ:RLMDD) from a hold rating to a buy rating in a research report report published on Wednesday morning. The firm currently has $5.25 price objective on the stock.

According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York. “

Related posts

Leave a Comment